| 货号 | HW310016 |
|---|---|
| 品牌 | abinScience |
| 种属反应性 | Human |
| 应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| 宿主 | Humanized |
| 同种型 | IgG1-kappa |
| 表达系统 | Mammalian Cells |
| 克隆类型 | Monoclonal |
| 靶标 | GPC3, MXR7, GTR2-2, Glypican-3, Intestinal protein OCI-5, OCI5 |
| 内毒素水平 | Please contact the lab for this information. |
| 纯度 | >95% purity as determined by SDS-PAGE. |
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
| Accession号 | P51654 |
| 状态 | Liquid |
| 保存溶液 | 0.01M PBS, pH 7.4. |
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| 别名 | GC33, RG7686, RO5137382, 1365267-33-9 |
| 背景 | Codrituzumab is a humanized monoclonal antibody targeted at glypican-3 (GPC3), which is a member of the glypican family. This drug is developed by Chugai Pharmaceutical in combination with Roche and has been investigated in the treatment of liver cancer. The specific expression of GPC3 is high in hepatocellular carcinoma (HCC) tissues, which suggests that GPC3 has obvious sensitivity and specificity in the diagnosis of hepatocellular carcinoma, and can be used as a new target for the treatment of hepatocellular carcinoma. Codrituzumab did not show significant inhibition of GPC3 in the phase I trial in combined with sorafenib and the phase II trial placebo-controlled study in patients with advanced liver cancer. Codrituzumab did not show significant inhibition of GPC3 in phase I trials and phase II trials combined with sorafenib in patients with advanced liver cancer. However, the effect of codrituzumab in the treatment of liver cancer is still under study. In 2018, researchers conducted trials such as the distribution of codrituzumab and the impact of overall survival in patients with hepatocellular carcinoma. In the combined analysis of tumor cell surface antigen GPC3 and NK cell surface antigen CD16 in patients with liver cancer, it was found that codrituzumab only had a certain therapeutic effect on patients with high expression level of GPC3 and CD16. These results suggest that GPC3 and CD16 can be used as a composite biomarker to select hepatocellular carcinoma patients for codrituzuma. • Cloning and characterization of human cDNAs encoding a protein with high homology to rat intestinal development protein OCI-5., PMID:9133586 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
SEC-HPLC detection for Research Grade Codrituzumab.
Detects GPC3 in indirect ELISAs.
7X24小时产品咨询热线：027--87433958(9:00-18:00)，或扫描下方产品专员二维码或在线留言
武汉东湖新技术开发区神墩四路666号研发楼B区3层东
24小时产品查询
扫一扫关注我们
专属渠道经理
